High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion-Reference-Cited by-同舟云学术

High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion

Published:2022-08-29 Issue:1 Volume:30 Page:51-61
ISSN:0929-1903
Container-title:Cancer Gene Therapy
language:en
Short-container-title:Cancer Gene Ther

Author:

Caballero Ana Carolina^ORCID,Escribà-Garcia Laura,Pujol-Fernández Paula,Escudero-López Eva,Ujaldón-Miró Cristina,Montserrat-Torres Rosanna,Sierra Jorge,Alvarez-Fernández Carmen,Briones Javier

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology,Molecular Medicine

Link

https://www.nature.com/articles/s41417-022-00518-6.pdf

Reference60 articles.

1. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38 LP–177ra38.

2. Grover NS, Savoldo B. Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer. 2019;19:1–8.

3. Dai H, Wang Y, Lu X, Han W. Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst. 2016;108. https://doi.org/10.1093/jnci/djv439.

4. Strati P, Neelapu SS. Chimeric antigen receptor–engineered T cell therapy in lymphoma. Curr Oncol Rep. 2019;21. https://doi.org/10.1007/s11912-019-0789-z.

5. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Maryalice SS, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33:540–9.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction to: High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion;Cancer Gene Therapy;2022-12-02